Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.
Estimates of SARS-CoV-2 transmission rates have significant public health policy implications since they shed light on the severity of illness in various groups and aid in strategic deployment of diagnostics, treatment and vaccination. Population-based investigations have not been conducted in Ghana...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLOS Global Public Health |
| Online Access: | https://doi.org/10.1371/journal.pgph.0001851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329950995251200 |
|---|---|
| author | Irene Owusu Donkor Sedzro Kojo Mensah Duah Dwomoh Jewelna Akorli Benjamin Abuaku Yvonne Ashong Millicent Opoku Nana Efua Andoh Jeffrey Gabriel Sumboh Sally-Ann Ohene Ama Akyampomaa Owusu-Asare Joseph Quartey Edward Dumashie Elvis Suatey Lomotey Daniel Adjei Odumang Grace Opoku Gyamfi Christopher Dorcoo Millicent Selassie Afatodzie Dickson Osabutey Rahmat Bint Yussif Ismail Isaac Quaye Samuel Bosomprah Vincent Munster Kwadwo Ansah Koram |
| author_facet | Irene Owusu Donkor Sedzro Kojo Mensah Duah Dwomoh Jewelna Akorli Benjamin Abuaku Yvonne Ashong Millicent Opoku Nana Efua Andoh Jeffrey Gabriel Sumboh Sally-Ann Ohene Ama Akyampomaa Owusu-Asare Joseph Quartey Edward Dumashie Elvis Suatey Lomotey Daniel Adjei Odumang Grace Opoku Gyamfi Christopher Dorcoo Millicent Selassie Afatodzie Dickson Osabutey Rahmat Bint Yussif Ismail Isaac Quaye Samuel Bosomprah Vincent Munster Kwadwo Ansah Koram |
| author_sort | Irene Owusu Donkor |
| collection | DOAJ |
| description | Estimates of SARS-CoV-2 transmission rates have significant public health policy implications since they shed light on the severity of illness in various groups and aid in strategic deployment of diagnostics, treatment and vaccination. Population-based investigations have not been conducted in Ghana to identify the seroprevalence of SARS-CoV-2. We conducted an age stratified nationally representative household study to determine the seroprevalence of SARS-CoV-2 and identify risk factors between February and December 2021. Study participants, 5 years and older regardless of prior or current infection COVID-19 infection from across Ghana were included in the study. Data on sociodemographic characteristics, contact with an individual with COVID-19-related symptoms, history of COVID-19-related illness, and adherence to infection prevention measures were collected. Serum obtained was tested for total antibodies with the WANTAI ELISA kit. The presence of antibodies against SAR-COV-2 was detected in 3,476 of 5,348 participants, indicating a seroprevalence of 67.10% (95% CI: 63.71-66.26). Males had lower seroprevalence (65.8% [95% CI: 63.5-68.04]) than females (68.4% [95% CI: 66.10-69.92]). Seroprevalence was lowest in >20 years (64.8% [95% CI: 62.36-67.19]) and highest among young adults; 20-39 years (71.1% [95% CI 68.83,73.39]). Seropositivity was associated with education, employment status and geographic location. Vaccination status in the study population was 10%. Exposure is more likely in urban than rural areas thus infection prevention protocols must be encouraged and maintained. Also, promoting vaccination in target groups and in rural areas is necessary to curb transmission of the virus. |
| format | Article |
| id | doaj-art-b79bb5314462416eb4b84a1195b7ffa3 |
| institution | Kabale University |
| issn | 2767-3375 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLOS Global Public Health |
| spelling | doaj-art-b79bb5314462416eb4b84a1195b7ffa32025-08-20T03:47:07ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752023-01-0135e000185110.1371/journal.pgph.0001851Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey.Irene Owusu DonkorSedzro Kojo MensahDuah DwomohJewelna AkorliBenjamin AbuakuYvonne AshongMillicent OpokuNana Efua AndohJeffrey Gabriel SumbohSally-Ann OheneAma Akyampomaa Owusu-AsareJoseph QuarteyEdward DumashieElvis Suatey LomoteyDaniel Adjei OdumangGrace Opoku GyamfiChristopher DorcooMillicent Selassie AfatodzieDickson OsabuteyRahmat Bint Yussif IsmailIsaac QuayeSamuel BosomprahVincent MunsterKwadwo Ansah KoramEstimates of SARS-CoV-2 transmission rates have significant public health policy implications since they shed light on the severity of illness in various groups and aid in strategic deployment of diagnostics, treatment and vaccination. Population-based investigations have not been conducted in Ghana to identify the seroprevalence of SARS-CoV-2. We conducted an age stratified nationally representative household study to determine the seroprevalence of SARS-CoV-2 and identify risk factors between February and December 2021. Study participants, 5 years and older regardless of prior or current infection COVID-19 infection from across Ghana were included in the study. Data on sociodemographic characteristics, contact with an individual with COVID-19-related symptoms, history of COVID-19-related illness, and adherence to infection prevention measures were collected. Serum obtained was tested for total antibodies with the WANTAI ELISA kit. The presence of antibodies against SAR-COV-2 was detected in 3,476 of 5,348 participants, indicating a seroprevalence of 67.10% (95% CI: 63.71-66.26). Males had lower seroprevalence (65.8% [95% CI: 63.5-68.04]) than females (68.4% [95% CI: 66.10-69.92]). Seroprevalence was lowest in >20 years (64.8% [95% CI: 62.36-67.19]) and highest among young adults; 20-39 years (71.1% [95% CI 68.83,73.39]). Seropositivity was associated with education, employment status and geographic location. Vaccination status in the study population was 10%. Exposure is more likely in urban than rural areas thus infection prevention protocols must be encouraged and maintained. Also, promoting vaccination in target groups and in rural areas is necessary to curb transmission of the virus.https://doi.org/10.1371/journal.pgph.0001851 |
| spellingShingle | Irene Owusu Donkor Sedzro Kojo Mensah Duah Dwomoh Jewelna Akorli Benjamin Abuaku Yvonne Ashong Millicent Opoku Nana Efua Andoh Jeffrey Gabriel Sumboh Sally-Ann Ohene Ama Akyampomaa Owusu-Asare Joseph Quartey Edward Dumashie Elvis Suatey Lomotey Daniel Adjei Odumang Grace Opoku Gyamfi Christopher Dorcoo Millicent Selassie Afatodzie Dickson Osabutey Rahmat Bint Yussif Ismail Isaac Quaye Samuel Bosomprah Vincent Munster Kwadwo Ansah Koram Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey. PLOS Global Public Health |
| title | Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey. |
| title_full | Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey. |
| title_fullStr | Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey. |
| title_full_unstemmed | Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey. |
| title_short | Modeling SARS-CoV-2 antibody seroprevalence and its determinants in Ghana: A nationally representative cross-sectional survey. |
| title_sort | modeling sars cov 2 antibody seroprevalence and its determinants in ghana a nationally representative cross sectional survey |
| url | https://doi.org/10.1371/journal.pgph.0001851 |
| work_keys_str_mv | AT ireneowusudonkor modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT sedzrokojomensah modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT duahdwomoh modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT jewelnaakorli modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT benjaminabuaku modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT yvonneashong modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT millicentopoku modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT nanaefuaandoh modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT jeffreygabrielsumboh modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT sallyannohene modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT amaakyampomaaowusuasare modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT josephquartey modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT edwarddumashie modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT elvissuateylomotey modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT danieladjeiodumang modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT graceopokugyamfi modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT christopherdorcoo modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT millicentselassieafatodzie modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT dicksonosabutey modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT rahmatbintyussifismail modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT isaacquaye modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT samuelbosomprah modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT vincentmunster modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey AT kwadwoansahkoram modelingsarscov2antibodyseroprevalenceanditsdeterminantsinghanaanationallyrepresentativecrosssectionalsurvey |